Jasper Therapeutics (JSPR) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jasper Therapeutics (JSPR) has outperformed TScan Therapeutics (TCRX) over the past year, losing 76.7% versus a loss of 88.5%. Over five years, TCRX leads with a -96.6% price change compared with -99.7% for JSPR. Jasper Therapeutics is the larger company by market cap ($19.0 million vs $15.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JSPR | TCRX |
|---|---|---|
| Share price | $0.5709 | $0.2352 |
| Market cap | $19.00M | $15.94M |
| 1-day change | +1.95% | +3.03% |
| YTD return | -69.40% | -77.18% |
| 1-year return | -76.67% | -88.47% |
| 5-year return | -99.66% | -96.62% |
| EPS (TTM) | $-1.04 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.69 | $2.57 |
| 52-week low | $0.315 | $0.224 |
| Distance from 52-week high | -78.78% | -90.85% |
| Analyst consensus | none | hold |
| Avg. price target upside | +3403.24% | +325.17% |
| Average volume | 1.37M | 783.59K |
| Shares outstanding | 33.27M | 63.50M |
| Employees | — | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JSPR has outperformed TCRX by 11.8 percentage points over the past year.
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
JSPR vs TCRX FAQ
Which is bigger, Jasper Therapeutics or TScan Therapeutics?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $19.00M compared with $15.94M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, JSPR or TCRX?
JSPR returned -76.67% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Jasper Therapeutics and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.